However, despite the incredible clinical advance in HCC treatment represented by PD-1-PD-L1 interaction inhibitors, a recent phase III trial in second-line comparing the PD-1 inhibitor Pembrolizumab vs. placebo failed to improve overall survival (OS) and progression-free survival (PFS) [177]. The gene discussed is CD274; the disease is hepatocellular carcinoma.